# Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee

> **NCT02697773** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 698 (actual)

## Conditions studied

- Osteoarthritis, Knee
- Osteoarthritis, Hip

## Interventions

- **OTHER:** Placebo
- **BIOLOGICAL:** Tanezumab 2.5 mg
- **BIOLOGICAL:** Tanezumab 2.5mg/5mg

## Key facts

- **NCT ID:** NCT02697773
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-21
- **Primary completion:** 2017-12-05
- **Final completion:** 2018-05-14
- **Target enrollment:** 698 (ACTUAL)
- **Last updated:** 2021-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02697773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02697773, "Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02697773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*